Karyopharm Therapeutics Inc. reported fourth‑quarter and full‑year 2025 results on February 12, 2026, with total revenue of $146.1 million and U.S. XPOVIO net product revenue of $114.9 million. The company posted a net loss of $102.2 million for the quarter and a net loss of $196 million for the year, largely driven by operating expenses and a $62.4 million loss on debt extinguishment. The adjusted earnings per share of $-2.23 beat the consensus estimate of $-2.26, a beat of $0.03 per share.
The results were slightly better than the prior year in terms of revenue, which rose 0.5 % to $146.1 million from $145.2 million in 2024, but the net loss widened to $196 million from $143.1 million in 2023. In the fourth quarter, revenue of $34.08 million fell 11.5 % from $30.5 million in Q4 2024 and missed the consensus estimate of $36.17 million. The Q4 net loss of $102.2 million was larger than the $41.8 million loss recorded in Q4 2023, reflecting higher operating costs and the one‑time debt extinguishment charge.
U.S. XPOVIO net product revenue grew 1.9 % to $114.9 million, the company’s only product line, indicating modest growth in its core franchise. The company’s guidance for 2026 maintains a total revenue range of $130–$150 million and a U.S. XPOVIO net product revenue range of $115–$130 million, unchanged from the prior guidance. Management emphasized that the guidance reflects confidence in the company’s commercial foundation while awaiting critical Phase 3 trial readouts in myelofibrosis and endometrial cancer.
"As we enter 2026, Karyopharm is approaching a defining period marked by important upcoming clinical milestones and a continued focus on disciplined execution, positioning the Company at a potential inflection point," CEO Richard Paulson said. "While selinexor has established a durable commercial foundation in multiple myeloma within a highly competitive treatment landscape, our late‑stage programs in myelofibrosis and endometrial cancer represent an opportunity to fundamentally expand the impact and scale of our franchise." The company also noted that it is actively evaluating a range of financing and strategic options to maintain flexibility as it approaches key clinical milestones.
The revenue miss relative to consensus highlights headwinds in the commercial market, while the EPS beat suggests that cost controls and the one‑time debt extinguishment charge were offset by disciplined operating performance. The company’s cash runway is expected to fund operations only into the second quarter of 2026, underscoring the importance of the upcoming trial readouts and potential financing options for sustaining growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.